Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-04 15:30 | 2025-11-26 | MAIA | MAIA Biotechnology, Inc. | Vitoc Vlad | Director, Officer, 10% owner | BUY | $1.11 | 72,000 | $79,848 | 903,421 |
| 2025-12-05 00:15 | 2025-12-02 | BMEA | Biomea Fusion, Inc. | Hitchcock Michael J.M. | Director, Officer | BUY | $0.99 | 100,000 | $99,180 | 115,000 |
| 2025-12-05 00:05 | 2025-12-03 | VERA | Vera Therapeutics, Inc. | Turner William D. | Officer | OPT+S | $40.00 | 10,000 | $400,000 | 22,500 |
| 2025-12-05 03:32 | 2025-12-02 | MNKD | MANNKIND CORP | Castagna Michael | Director, Officer | OPT+S | $5.57 | 107,920 | $601,114 | 2,504,792 |
| 2025-12-05 03:00 | 2025-12-02 | QTTB | Q32 Bio Inc. | Kalowski Lee | Officer | SELL | $3.46 | 9,072 | $31,395 | 39,938 |
| 2025-12-05 03:00 | 2025-12-02 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | Director, Officer | SELL | $3.46 | 22,506 | $77,871 | 99,000 |
| 2025-12-05 02:19 | 2025-12-02 | HOWL | Werewolf Therapeutics, Inc. | MPM BioVentures 2014, L.P. | SELL | $0.92 | 199,732 | $183,274 | 4,784,111 | |
| 2025-12-05 00:54 | 2025-12-02 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $10.11 | 6,000 | $60,640 | 420,818 |
| 2025-12-05 05:30 | 2025-12-02 | CRMD | CorMedix Inc. | Dillione Janet | Director | OPT+S | $10.00 | 46,657 | $466,570 | 48,473 |
| 2025-12-05 00:02 | 2025-11-24 | KALV | KalVista Pharmaceuticals, Inc. | Sweeny Nicole | Officer | OPT+S | $13.45 | 3,813 | $51,289 | 39,728 |
| 2025-12-05 03:56 | 2025-12-02 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $3.61 | 6,500 | $23,481 | 0 |
| 2025-12-05 03:27 | 2025-12-02 | MNKD | MANNKIND CORP | Thomson David | Officer | OPT+S | $5.57 | 147,780 | $823,135 | 841,719 |
| 2025-12-05 04:11 | 2025-12-02 | ALMS | Alumis Inc. | AKKARAJU SRINIVAS | Director | BUY | $7.79 | 262,027 | $2,039,906 | 1,078,876 |
| 2025-12-05 03:39 | 2025-12-02 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | Director, Officer, 10% owner | OPT+S | $145.66 | 79,973 | $11,648,579 | 7,229 |
| 2025-12-05 01:26 | 2025-12-04 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Sibold William John | Director, Officer | OPT+S | $575.34 | 2,400 | $1,380,816 | 150,074 |
| 2025-12-05 02:20 | 2025-12-02 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.92 | 128,185 | $117,623 | 3,068,278 |
| 2025-12-05 02:18 | 2025-12-02 | HOWL | Werewolf Therapeutics, Inc. | GADICKE ANSBERT | SELL | $0.92 | 199,732 | $183,274 | 4,784,111 | |
| 2025-12-05 00:57 | 2025-12-02 | GALT | GALECTIN THERAPEUTICS INC | 10X Fund, L.P. | 10% owner | SELL | $5.68 | 150,000 | $851,700 | 5,682,207 |
| 2025-12-05 02:34 | 2025-12-03 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $41.00 | 7,040 | $288,607 | 49,760 |
| 2025-12-04 04:00 | 2025-12-01 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Officer | OPT+S | $32.98 | 3,333 | $109,929 | 84,974 |
| 2025-12-04 01:02 | 2025-12-01 | NUVB | Nuvation Bio Inc. | Liu Dongfang | Officer | OPT+S | $7.82 | 150,000 | $1,173,255 | 18,000 |
| 2025-12-04 01:10 | 2025-12-01 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $39.92 | 41,575 | $1,659,487 | 25,640 |
| 2025-12-04 01:11 | 2025-12-01 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $39.87 | 69,582 | $2,773,956 | 47,260 |
| 2025-12-04 01:23 | 2025-12-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | SELL | $30.21 | 10,000 | $302,133 | 79,744 |
| 2025-12-04 01:24 | 2025-12-01 | ARQT | Arcutis Biotherapeutics Inc. | Matsuda Masaru | Officer | SELL | $30.23 | 1,657 | $50,091 | 150,641 |
| 2025-12-04 00:28 | 2025-12-01 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Officer | OPT+S | $45.02 | 5,000 | $225,100 | 66,837 |
| 2025-12-04 05:52 | 2025-12-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer | SELL | $29.02 | 15,000 | $435,356 | 686,907 |
| 2025-12-04 04:20 | 2025-12-02 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | OPT+S | $30.22 | 4,576 | $138,268 | 19,612 |
| 2025-12-04 04:23 | 2025-12-02 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | OPT+S | $30.22 | 4,020 | $121,468 | 15,156 |
| 2025-12-04 01:39 | 2025-12-01 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $37.53 | 6,864 | $257,610 | 370,964 |
| 2025-12-04 04:20 | 2025-11-28 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Director, Officer | SELL | $45.01 | 97 | $4,366 | 31,205 |
| 2025-12-04 00:30 | 2025-12-01 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $4.47 | 4,115 | $18,394 | 50,290 |
| 2025-12-04 00:30 | 2025-12-01 | ANNX | Annexon, Inc. | Choi Jung | Director | BUY | $4.19 | 33,000 | $138,270 | 33,000 |
| 2025-12-04 04:22 | 2025-12-02 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. MD | Director | OPT+S | $30.22 | 2,136 | $64,541 | 51,305 |
| 2025-12-04 00:30 | 2025-12-01 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | Officer | OPT+S | $35.01 | 20,000 | $700,202 | 92,083 |
| 2025-12-04 00:39 | 2025-12-01 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Bedrosian Camille L | Officer | SELL | $14.35 | 6,580 | $94,418 | 175,756 |
| 2025-12-04 01:08 | 2025-12-01 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | SELL | $195.84 | 467 | $91,457 | 44,121 |
| 2025-12-04 04:11 | 2025-12-01 | FOLD | AMICUS THERAPEUTICS, INC. | Campbell Bradley L | Director, Officer | OPT+S | $10.01 | 14,587 | $146,011 | 1,137,282 |
| 2025-12-04 01:09 | 2025-12-02 | ENTA | ENANTA PHARMACEUTICALS INC | Capps Kathleen S. | Officer | SELL | $13.96 | 207 | $2,890 | 8,700 |
| 2025-12-04 01:05 | 2025-12-02 | ENTA | ENANTA PHARMACEUTICALS INC | Trout Harry R. III | Officer | SELL | $13.96 | 380 | $5,305 | 16,890 |
| 2025-12-04 01:59 | 2025-12-02 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | Officer | OPT+S | $578.34 | 4,173 | $2,413,417 | 10,440 |
| 2025-12-04 00:01 | 2025-12-01 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | OPT+S | $206.98 | 8,895 | $1,841,100 | 83,111 |
| 2025-12-04 05:19 | 2025-12-02 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $80.08 | 20,000 | $1,601,526 | 1,235 |
| 2025-12-04 04:53 | 2025-12-01 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $79.52 | 20,000 | $1,590,490 | 7,904 |
| 2025-12-04 04:36 | 2025-12-01 | CORT | CORCEPT THERAPEUTICS INC | Lyon Joseph Douglas | Officer | OPT+S | $79.53 | 5,000 | $397,632 | 10,277 |
| 2025-12-04 04:14 | 2025-12-01 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $79.77 | 40,000 | $3,190,796 | 2,701,370 |
| 2025-12-04 03:01 | 2025-12-01 | IONS | IONIS PHARMACEUTICALS INC | WENDER JOSEPH H | Director | SELL | $80.82 | 28,000 | $2,262,848 | 36,035 |
| 2025-12-04 01:20 | 2025-12-02 | PTCT | PTC THERAPEUTICS, INC. | Klein Matthew B. | Director, Officer | SELL | $79.07 | 3,428 | $271,052 | 349,964 |
| 2025-12-03 00:30 | 2025-11-28 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $108.58 | 4,000 | $434,319 | 48,034 |
| 2025-12-03 00:34 | 2025-12-01 | LQDA | Liquidia Corp | Schundler Russell | Officer | OPT+S | $32.19 | 1,072 | $34,508 | 577,288 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.